Schwab Charles Investment Management Inc. raised its holdings in AtriCure Inc. (NASDAQ:ATRC) by 5.6% during the third quarter, Holdings Channel reports. The institutional investor owned 170,101 shares of the medical device company’s stock after acquiring an additional 9,070 shares during the period. Schwab Charles Investment Management Inc.’s holdings in AtriCure were worth $3,806,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in ATRC. State Street Corp grew its holdings in shares of AtriCure by 4.0% during the 2nd quarter. State Street Corp now owns 617,405 shares of the medical device company’s stock worth $14,971,000 after purchasing an additional 23,790 shares in the last quarter. UBS Asset Management Americas Inc. acquired a new stake in shares of AtriCure during the 2nd quarter worth approximately $315,000. Vanguard Group Inc. grew its holdings in shares of AtriCure by 3.8% during the 2nd quarter. Vanguard Group Inc. now owns 1,446,732 shares of the medical device company’s stock worth $35,083,000 after purchasing an additional 52,761 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of AtriCure by 11.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 199,693 shares of the medical device company’s stock worth $4,842,000 after purchasing an additional 20,107 shares in the last quarter. Finally, Parametric Portfolio Associates LLC grew its holdings in shares of AtriCure by 76.0% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 60,949 shares of the medical device company’s stock worth $1,478,000 after purchasing an additional 26,327 shares in the last quarter. 86.17% of the stock is currently owned by hedge funds and other institutional investors.

AtriCure Inc. (NASDAQ:ATRC) opened at $17.73 on Friday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.65 and a current ratio of 2.28. AtriCure Inc. has a 52-week low of $14.78 and a 52-week high of $25.18.

AtriCure (NASDAQ:ATRC) last posted its earnings results on Wednesday, November 1st. The medical device company reported ($0.22) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.24) by $0.02. The business had revenue of $42.20 million during the quarter, compared to the consensus estimate of $43.44 million. AtriCure had a negative return on equity of 20.28% and a negative net margin of 19.40%. AtriCure’s revenue was up 10.1% on a year-over-year basis. During the same quarter last year, the company earned ($0.21) EPS. sell-side analysts anticipate that AtriCure Inc. will post -0.96 earnings per share for the current fiscal year.

Several analysts have recently weighed in on the company. Zacks Investment Research lowered AtriCure from a “hold” rating to a “sell” rating in a report on Tuesday, September 26th. Canaccord Genuity decreased their price objective on AtriCure from $28.00 to $24.00 and set a “buy” rating on the stock in a report on Thursday, November 2nd. Needham & Company LLC decreased their price objective on AtriCure from $26.00 to $25.00 and set a “buy” rating on the stock in a report on Thursday, November 2nd. TheStreet lowered AtriCure from a “c-” rating to a “d+” rating in a report on Wednesday, November 29th. Finally, ValuEngine lowered AtriCure from a “hold” rating to a “sell” rating in a report on Wednesday, November 15th. Two analysts have rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $24.67.

In related news, CFO M. Andrew Wade sold 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $18.41, for a total transaction of $36,820.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director B Kristine Johnson bought 1,500 shares of the business’s stock in a transaction that occurred on Wednesday, November 8th. The shares were bought at an average price of $18.36 per share, with a total value of $27,540.00. Following the transaction, the director now directly owns 10,969 shares in the company, valued at $201,390.84. The disclosure for this purchase can be found here. 10.00% of the stock is owned by company insiders.

TRADEMARK VIOLATION WARNING: “AtriCure Inc. (ATRC) Shares Bought by Schwab Charles Investment Management Inc.” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at https://www.thecerbatgem.com/2018/01/14/atricure-inc-atrc-shares-bought-by-schwab-charles-investment-management-inc.html.

About AtriCure

AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.

Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure Inc. (NASDAQ:ATRC).

Institutional Ownership by Quarter for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.